menu
    • menu

    Company profile for Inipharm

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Inipharm, we’re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm’s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases. There is extensive evidence that certain variants of this gene are associated with lower rates of disea...
    At Inipharm, we’re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm’s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases. There is extensive evidence that certain variants of this gene are associated with lower rates of disease, less severe disease and reduced levels of liver damage, including inflammation and fibrosis. It is building on novel insights into the biologic activity of HSD17B13 to advance a collection of potent and selective.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InipharmUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    500 108th Avenue Ne, Suite 1100 Bellevue WA,
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://inipharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inipharm to present Pharmacokinetic data from phase 1 trial of INI-822 at EASL
    Inipharm to present Pharmacokinetic data from phase 1 trial of INI-822 at EASL

    25 May 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169342&sid=2

    PHARMABIZ
    25 May 2024
    Share Share
    Inipharm To Present INI-822 PK Phase 1 Data
    Inipharm To Present INI-822 PK Phase 1 Data

    22 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240522608190/en

    BUSINESSWIRE
    22 May 2024
    Share Share
    Inipharm Initiates Dosing in Ph 1 Study of Small Molecule Inhibitor of HSD17B13
    Inipharm Initiates Dosing in Ph 1 Study of Small Molecule Inhibitor of HSD17B13

    30 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231130655005/en

    BUSINESSWIRE
    30 Nov 2023
    Share Share
    Inipharm’s Development Candidate INI-822 Shows Improvements in Markers of Liver Homeostasis
    Inipharm’s Development Candidate INI-822 Shows Improvements in Markers of Liver Homeostasis

    07 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230607005202/en

    BUSINESSWIRE
    07 Jun 2023
    Share Share
    Inipharm to Present Data on Anti-Fibrotic Targeting HSD17B13
    Inipharm to Present Data on Anti-Fibrotic Targeting HSD17B13

    25 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221025005402/en

    BUSINESSWIRE
    25 Oct 2022
    Share Share
    Inipharm Appoints Chuhan Chung, M.D, as CMO to Advance HSD17B13 Program
    Inipharm Appoints Chuhan Chung, M.D, as CMO to Advance HSD17B13 Program

    08 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220608005325/en

    BUSINESSWIRE
    08 Jun 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search